VKTX: the balance sheet

MyFinsight

For the quarter ending 2025-09-30, VKTX has $739,415K in assets. $26,385K in debts. $100,376K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Cash and cash equivalents	100,376	33,880	37,940	50,347
Short-term investments available for sale	614,194	773,844	813,918	880,093
Prepaid clinical trial and preclinical study costs	21,891	16,478	13,300	4,476
Prepaid expenses and other current assets	2,242	2,815	865	1,733
Total current assets	738,703	827,017	866,023	936,649
Right-of-use assets	666	780	892	1,113
Deferred financing costs	0	8	32	80
Deposits	46	46	46	46
Total assets	739,415	827,851	866,993	937,888

Accounts payable	4,413	5,494	7,702	254
Other accrued liabilities	21,217	26,018	11,373	24,951
Lease liability, current	437	468	498	480
Total current liabilities	26,067	31,980	19,573	25,685
Lease liability, net of current portion	318	410	502	755
Total long-term liabilities	318	410	502	755
Total liabilities	26,385	32,390	20,075	26,440
Common stock, 0.00001 par value 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 112,446,961 shares issued and outstanding at september 30, 2025 and 111,573,519 shares issued and outstanding at december 31, 2024	1	1	1	1
Treasury stock at cost, no shares at september 30, 2025 and december 31, 2024	0	0	0	0
Additional paid-in capital	1,402,539	1,394,723	1,380,669	1,362,305
Accumulated deficit	-689,884	-599,097	-533,536	-452,490
Accumulated other comprehensive loss	374	-166	-216	1,632
Total stockholders equity	713,030	795,461	846,918	911,448
Total liabilities and stockholders equity	739,415	827,851	866,993	937,888